AIM ImmunoTech (AIM) Income from Continuing Operations (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Income from Continuing Operations came in at 3224000.0 in Q1 2026, up 15.49% YoY from 2791547.89 in Q1 2025, and little changed on a QoQ basis from 3234000.0 in Q4 2025.
AIM ImmunoTech (AIM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Income from Continuing Operations data on file, last reported at 3224000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 15.49% year-over-year to 3224000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14029000.0 (up 32.69% YoY) and the FY2025 annual result came in at 58516000.0, up 6.6% from the prior year.
- Income from Continuing Operations steadied at 3224000.0 in Q1 2026, from 3234000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2635000.0 in Q3 2025 to a low of 14141000.0 in Q4 2023.
- A 5-year average of 5671647.06 and a median of 4936000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 151.04% — and 2024, when it soared 57.66%.
- Tracing AIM's Income from Continuing Operations over 5 years: stood at 5633000.0 in 2022, then sank by 151.04% to 14141000.0 in 2023, then surged by 57.66% to 5987000.0 in 2024, then jumped by 45.98% to 3234000.0 in 2025, then gained by 0.31% to 3224000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3224000.0 (Q1 2026), 3234000.0 (Q4 2025), and 2635000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | -3.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.13 Mn |
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -3.23 Mn |
| Sep 30, 2025 | -2.64 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Dec 31, 2024 | -5.99 Mn |
| Sep 30, 2024 | -4.71 Mn |
| Jun 30, 2024 | -6.33 Mn |
| Mar 31, 2024 | -8.31 Mn |
| Dec 31, 2023 | -14.14 Mn |
| Sep 30, 2023 | -8.36 Mn |
| Jun 30, 2023 | -5.66 Mn |
| Mar 31, 2023 | -4.50 Mn |
| Dec 31, 2022 | -5.63 Mn |
| Sep 30, 2022 | -6.76 Mn |
| Jun 30, 2022 | -4.86 Mn |
| Mar 31, 2022 | -3.34 Mn |
| Dec 31, 2021 | -7.45 Mn |
| Sep 30, 2021 | -5.07 Mn |